{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 6 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Section 9.8.3.1', 'Used syringes will be destroyed at the', 'To clarify that a certificate of', 'IMP', 'trial site provided the trial site has', 'destruction is not required for used', 'accountability', 'procedures in place for such IMP', 'IMP.', 'destruction; this requires that the trial', 'site is able to issue a certificate', 'documenting the kit number(s) that', 'were destroyed.', 'To also allow shipment of sharps bins', 'Trial sites which do not have such IMP', 'to the CMO during the trial.', 'destruction procedures in place will', 'dispose used syringes in sharps bins', 'which will be shipped to the CMO-at', 'the end of the trial.', 'For more information about IMP', 'accountability, please refer to the', 'IMP handling manual.', 'Section 10.3.2.9', 'The second section consists of a', 'To correct the definition of extremes', 'EQ-5D-5L', 'vertical visual analogue scale anchored', 'in the vertical visual analogue scale.', \"at 0 ('the worst best health you can\", \"imagine') and 100 ('the best worst\", \"health you can imagine').\", 'Section 11.1', 'AEs must be collected from time of', 'To clarify how (S)AEs occurring in', 'Collection of', 'first trial-related activity after the', 'subjects entering LP0162-1337', 'adverse events', 'subject has signed the informed consent', '(ECZTEND) will be collected if', 'form (ICF) until completion of the', 'visits in LP0162-1339 overlap with', 'clinical trial (defined as the safety', 'visits in ECZTEND.', 'follow-up visit 16 weeks after last', 'injection of IMP). For subjects', 'entering the long-term extension trial', '(LP0162-1337, ECZTEND), any', '(S)AE with onset before the final', 'visit in LP0162-1339 should be', 'reported in LP0162-1339. If ongoing,', 'the (S)AE will also be recorded as', 'medical history in ECZTEND.', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 7 of 129', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Section 11.5.1', 'The text in the heading of the right', 'To clarify that additional information', 'Adverse events of', 'column was modified as follows:', 'is to be provided only if available and', 'special interest', 'Additional information to be provided', 'is not requirement.', 'Panel 10', '(if available\u00b9)', 'A footnote was added:', 'The additional data to be recorded', 'in the eCRF are not a requirement,', 'but are to be reported by the', 'investigator, if available, for example', 'as part of standard clinical practice.', 'Section 12.3.8.2', 'The following text is added:', 'To describe the statistical analyses of', 'Patient-reported', 'In the subgroup of subjects with', 'the new endpoints.', 'outcomes', 'either HADS anxiety or HADS', 'depression subscale score >8 at', 'baseline, the proportion of subjects', 'with both HADS anxiety and HADS', 'depression subscale score <8', 'at', 'Week 16 will be summarised by', 'treatment group and analysed as', 'described for the primary analysis of', 'the primary estimand for the', 'primary endpoints.', 'In the subgroup of subjects with a', 'baseline POEM score >4, the', 'proportion of subjects with a', 'reduction in POEM score >4 at', 'Week 16 will be summarised by', 'treatment group and analysed as', 'described for the primary analysis of', 'the primary estimand for the', 'primary endpoints.', 'Section 12.3.9.1', 'SAEs and AESIs will be evaluated', 'Tabulation and listings are considered', 'Adverse events', 'separately. and aA narrative for each', 'a more practical and informative way', 'SAE will be given. AESIs and AEs', 'of presenting AESIs. This will enable', 'leading to withdrawal from trial or', 'easier overview of the individual', 'permanent discontinuation of IMP will', 'cases as well as sorting and pooling', 'be tabulated and listed.', 'of data from other trials.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}